Track Orchestra BioMed Holdings's total revenue ($32M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Orchestra BioMed Holdings (OBIO) currently reports a total revenue of $32M as of June 2026. That compares with $2.9M in the prior-year period — up 986.1% year over year. That is below the sector sector average of $1.3B. Use the charts on this page to explore Orchestra BioMed Holdings's total revenue history and peer comparisons.
Orchestra BioMed Holdings's total revenue increased from $2.9M to $32M — a 986.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Orchestra BioMed Holdings's total revenue of $32M is lower than the its sector sector average of $1.3B. That is roughly 97.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Orchestra BioMed Holdings reported $32M in total revenue as of June 2026. That compares with $2.9M in the prior-year period — up 986.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $32M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.3B. From there, open related valuation or income-statement pages for Orchestra BioMed Holdings, and consider following OBIO for alerts when major investors trade the stock.